Page 132 - 中国全科医学2022-14

http://www.chinagp.net E-mail:zgqkyx@chinagp.net.cn ·1793·

medical treatment of Cushing's disease：effectiveness of chronic treatment
本文文献检索策略：
with the dopamine agonist cabergoline in patients unsuccessfully treated by
检索 PubMed 和 Web of Science 等数据库，关键词为
surgery［J］. J Clin Endocrinol Metab，2009，94（1）：223-230.
“Cushing's disease” “ACTH”和“ medical therapy”，检
DOI：10.1210/jc.2008-1533.
索时间为建库至 2021 年 7 月。并收集 2021 年 7 月前国内
［12］FERRIERE A，CORTET C，CHANSON P，et al. Cabergoline for
外公开发表的所有库欣病的药物治疗的相关研究。纳入标
Cushing's disease：a large retrospective multicenter study［J］.
准：文章内容与库欣病、药物治疗、促肾上腺皮质激素密
Eur J Endocrinol，2017，176（3）：305-314. DOI：10.1530/
切相关；同一领域选择新近文献或在权威杂志上发表的文
eje-16-0662.
章。排除标准：筛选重复性与无关的文献。
［13］NAKHLEH A，SAIEGH L，REUT M，et al. Cabergoline
参考文献 treatment for recurrent Cushing's disease during pregnancy［J］.
［1］PIVONELLO R，DE LEO M，COZZOLINO A，et al. The treatment Hormones：Athens，2016，15（3）：453-458. DOI：10.14310/
of Cushing's disease［J］. Endocr Rev，2015，36（4）：385-486. horm.2002.1685.
DOI：10.1210/er.2013-1048. ［14］FERONE D，GATTO F，ARVIGO M，et al. The clinical-
［2］LUQUE R M，GAHETE M D，HOCHGESCHWENDER U，et al. molecular interface of somatostatin，dopamine and their receptors in
Evidence that endogenous SST inhibits ACTH and ghrelin expression pituitary pathophysiology［J］. J Mol Endocrinol，2009，42（5）：
by independent pathways［J］. Am J Physiol Endocrinol Metab， 361-370. DOI：10.1677/jme-08-0162.
2006，291（2）：E395-403. DOI：10.1152/ajpendo.00038.2006. ［15］VÁZQUEZ-BORREGO M C，L-LÓPEZ F，GÁLVEZ-MORENO M
［3］COLAO A，PETERSENN S，NEWELL-PRICE J，et al. A，et al. A new generation somatostatin-dopamine analogue exerts
A 12-month phase 3 study of pasireotide in Cushing's disease［J］. potent antitumoral actions on pituitary neuroendocrine tumor cells
N Engl J Med，2012，366（10）：914-924. DOI： ［J］. Neuroendocrinology，2020，110（1/2）：70-82. DOI：
10.1056/nejmoa1105743. 10.1159/000500812.
［4］SCHOPOHL J，GU F，RUBENS R，et al. Pasireotide can induce ［16］GÜNTHER T，TULIPANO G，DOURNAUD P，et al. International
sustained decreases in urinary cortisol and provide clinical benefit in union of basic and clinical pharmacology. CV. somatostatin
patients with Cushing's disease：results from an open-ended，open- receptors：structure，function，ligands，and new nomenclature［J］.
label extension trial［J］. Pituitary，2015，18（5）：604-612. Pharmacol Rev，2018，70（4）：763-835. DOI：10.1124/
DOI：10.1007/s11102-014-0618-1. pr.117.015388.
［5］LACROIX A，GU F，GALLARDO W，et al. Efficacy and safety of ［17］ALBANI A，PEREZ-RIVAS L G，REINCKE M，et al.
once-monthly pasireotide in Cushing's disease：a 12 month clinical Pathogenesis of cushing disease：an update on the genetics of
trial［J］. Lancet Diabetes Endocrinol，2018，6（1）：17-26. corticotropinomas［J］. Endocr Pract，2018，24（10）：907-
DOI：10.1016/s2213-8587（17）30326-1. 914. DOI：10.4158/ep-2018-0111.
［6］FLESERIU M，PETERSENN S，BILLER B M K，et al. Long-term ［18］LIU N A，JIANG H，BEN-SHLOMO A，et al. Targeting zebrafish
efficacy and safety of once-monthly pasireotide in Cushing's disease： and murine pituitary corticotroph tumors with a cyclin-dependent
a Phase Ⅲ extension study［J］. Clin Endocrinol：Oxf，2019，91（6）： kinase （CDK） inhibitor［J］. PNAS，2011，108（20）：
776-785. DOI：10.1111/cen.14081. 8414-8419. DOI：10.1073/pnas.1018091108.
［7］PAWLIKOWSKI M，KUNERT-RADEK J，STEPIE H. Direct ［19］ARAKI T，LIU N A. Cell cycle regulators and lineage-specific
antiproliferative effect of dopamine agonists on the anterior pituitary therapeutic targets for cushing disease［J］. Front Endocrinol：
gland in organ culture［J］. J Endocrinol，1978，79（2）：245- Lausanne，2018，9：444. DOI：10.3389/fendo.2018.00444.
246. DOI：10.1677/joe.0.0790245. ［20］LIU N A，ARAKI T，CUEVAS-RAMOS D，et al. Cyclin E-mediated
［8］WANG Y W，LI J Y，TOHTI M，et al. The expression profile of human proopiomelanocortin regulation as a therapeutic target for
Dopamine D2 receptor，MGMT and VEGF in different histological cushing disease［J］. J Clin Endocrinol Metab，2015，100（7）：
subtypes of pituitary adenomas：a study of 197 cases and indications 2557-2564. DOI：10.1210/jc.2015-1606.
for the medical therapy［J］. J Exp Clin Cancer Res，2014，33： ［21］THEODOROPOULOU M，ARZBERGER T，GRUEBLER Y，
56. DOI：10.1186/s13046-014-0056-y. et al. Expression of epidermal growth factor receptor in neoplastic
［9］FERONE D，PIVONELLO C，VITALE G，et al. Molecular basis pituitary cells：evidence for a role in corticotropinoma cells［J］.
of pharmacological therapy in Cushing's disease［J］. Endocrine， J Endocrinol，2004，183（2）：385-394. DOI：10.1677/
2014，46（2）：181-198. DOI：10.1007/s12020-013-0098-5. joe.1.05616.
［10］FEELDERS R A，NEWELL-PRICE J，PIVONELLO R，et al. ［22］CHANDRA P，RAJARAM P，TICKU S，et al. Epidermal growth
Advances in the medical treatment of Cushing's syndrome［J］. factor receptor：Role in human cancer［J］. Indian J Dent Res，
Lancet Diabetes Endocrinol，2019，7（4）：300-312. DOI： 2017，28（6）：687. DOI：10.4103/ijdr.ijdr_534_16.
10.1016/s2213-8587（18）30155-4. ［23］TATSI C，FLIPPO C，STRATAKIS C A. Cushing syndrome：
［11］PIVONELLO R，DE MARTINO M C，CAPPABIANCA P，et al. The Old and new genes［J］. Best Pract Res Clin Endocrinol Metab，